Supernus Pharmaceuticals(US:SUPN) Globenewswireยท2025-02-25 21:01Core Insights - Supernus Pharmaceuticals reported strong financial results for Q4 and full year 2024, highlighting significant growth in core products and operating earnings [2][3][14] - The company anticipates continued growth in Qelbree and the launch of ONAPGO for Parkinson's disease in Q2 2025 [2][3] Financial Performance - Q4 2024 net sales of Qelbree increased by 60% to $74.4 million, while full year sales rose by 72% to $241.3 million compared to 2023 [3][14] - GOCOVRI's Q4 2024 net sales increased by 15% to $36.9 million, with full year sales up by 9% to $130.8 million [3][14] - Total revenues for full year 2024 reached $661.8 million, a 9% increase from 2023, with revenues excluding Trokendi XR and Oxtellar XR up by 25% [3][14] - Operating earnings for full year 2024 were $81.7 million, a significant recovery from an operating loss of $(5.3) million in 2023 [3][14] Product Pipeline Developments - ONAPGO, approved by the FDA, is set to launch in Q2 2025 as the first subcutaneous apomorphine infusion device for Parkinson's disease [3][5] - Qelbree's label has been updated to include new pharmacodynamic data, enhancing its profile for ADHD treatment [4] - Interim results from a Phase IV trial of Qelbree in adults with ADHD showed promising improvements in symptoms [4] Future Guidance - For full year 2025, Supernus projects total revenues between $600 million and $630 million, with adjusted operating earnings expected to be between $105 million and $130 million [3][12]